IM Cannabis Logo
CA44969Q2080

IM Cannabis

Ins Portfolio

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Dividenden-Strategie 0 / 15
HGI-Strategie 3 / 18
Levermann-Strategie -2 / 13
Powered by aktien.guide

News

  • Foto von IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management
    04.10. - 11:00 Uhr

    IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel , Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (each, a "Share") equal to the 10-day volume weighted average price of the Shares on Canadian Securities Exchange (the "Exchange") ending on the trading day preceding October 3, 2024. Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant"). » Mehr auf prnewswire.com

  • Foto von IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2
    02.10. - 12:00 Uhr

    IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2

    TORONTO and GLIL YAM, Israel , Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products. » Mehr auf prnewswire.com

  • Foto von IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
    11.09. - 12:30 Uhr

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel , Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. » Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte IM Cannabis einen Umsatz von 10,05 Mio und ein Nettoeinkommen von 2,06 Mio
(EUR) Juni 2024
YOY
Umsatz 10,05 Mio 10,02%
Bruttoeinkommen 575,00k 75,94%
Nettoeinkommen 2,06 Mio 19,49%
EBITDA 1,64 Mio 271,56%

Fundamentaldaten

Metrik Wert
Marktkapitalisierung
4,25 Mio
Anzahl Aktien
2,23 Mio
52 Wochen-Hoch/Tief
7,49 - 1,05
Dividenden Nein
Beta
1,68
KGV (PE Ratio)
0,35
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,90
KUV (PS Ratio)
0,08

Unternehmensprofil

IM Cannabis Corp. beschäftigt sich mit der Zucht, dem Anbau und der Lieferung von medizinischen Cannabisprodukten in Israel, Deutschland und Kanada. Das Unternehmen bietet Cannabisblüten und stammspezifische Cannabisextrakte unter der Marke IMC sowie Trockenblüten, Pre-Rolls und gepresstes Haschisch unter den Marken WAGNERS und Highland Grow an. Das Unternehmen beliefert medizinische Patienten und Freizeitkonsumenten. Die IM Cannabis Corp. hat ihren Hauptsitz in Tel Aviv-Yafo, Israel.

Name
IM Cannabis
CEO
Oren Shuster
Sitz Tel Aviv,
Israel
Website
Industrie
Körperpflegeprodukte
Börsengang
20.05.2020
Mitarbeiter 95

Ticker Symbole

Börse Symbol
NASDAQ
IMCC
🍪

Parqet nutzt Cookies. Erfahre Mehr